# Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Canonical URL: https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update
Ticker: SNSE
Company: Sensei Biotherapeutics
Source: Sensei Biotherapeutics
Published: 2026-05-15 11:30 EST
Original Source URL: https://investors.senseibio.com
## Summary

First patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer Topline Phase 2 data in patients with advanced endometrial cancer expected in second half 2026 BOSTON --(BUSINESS WIRE)--May 15, 2026-- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results

## Article Body
First patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer Topline Phase 2 data in patients with advanced endometrial cancer expected in second half 2026 BOSTON --(BUSINESS WIRE)--May 15, 2026-- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results
## Recent Company News
- 2026-05-15 11:30 EST — [Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Sensei Biotherapeutics
- 2026-05-05 11:30 EST — [Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-doses-first-patient-in-phase-1b-2-trial-of-piktor-in-hr-her2-advanced-breast-cancer) — Source: Sensei Biotherapeutics
- 2026-04-09 11:30 EST — [Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference) — Source: Sensei Biotherapeutics
- 2026-03-30 11:30 EST — [Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-reports-full-year-2025-financial-results-and-provides-corporate-update) — Source: Sensei Biotherapeutics
- 2026-03-17 10:00 EST — [Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Sensei Biotherapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)